Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763174 | 0.85 | LMNA (0.60) | ALDH1A1MAPTPOLBLTC4SRAB9A | |
| SCHEMBL7624466 | 0.82 | ALDH1A1 (1.00) | ALDH1A1MAPTPOLBLTC4SRAB9A | |
| SCHEMBL29355043 | 0.82 | ALDH1A1 (1.00) | ALDH1A1MAPTPOLBLTC4SRAB9A | |
| SCHEMBL6766219 | 0.81 | POLB (0.72) | ALDH1A1POLBRAB9ASMN1; SMN2LMNA | |
| SCHEMBL13885949 | 0.79 | ALDH1A1 (0.68) | ALDH1A1MAPTPOLBLTC4SRAB9A | |
| SCHEMBL6965655 | 0.76 | ALDH1A1 (0.71) | ALDH1A1MAPTPOLBLTC4SRAB9A | |
| Trovirdine SCHEMBL636095 | 0.76 | ALDH1A1 (0.71) | ALDH1A1MAPTLTC4SRAB9ASMN1; SMN2 | |
| SCHEMBL7224530 | 0.76 | LTC4S (0.87) | ALDH1A1MAPTPOLBLTC4SRAB9A | |
| SCHEMBL6231342 | 0.76 | ALDH1A1 (0.69) | ALDH1A1MAPTPOLBLTC4SRAB9A | |
| SCHEMBL21533494 | 0.75 | LMNA (0.73) | ALDH1A1MAPTPOLBRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727265-B2 | REVERSE TRANSCRIPTASE INHIBITORS FOR DRUG RESISTANT PATIENTS | PARKER HUGHES INSTITUTE | 2004-04-27 | — | — | US | disclosed |
| US-6689793-B2 | INHIBITORS OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE AND MULTI-DRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS REVERSE TRANSCRIPTASE | PARKER HUGHES INSTITUTE | 2004-02-10 | — | — | US | disclosed |
| US-20030186991-A1 | Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections | PARKER HUGHES INSTITUTE | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186991-A1 | Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections | TPMT, TERT, TET1 | ALDH1A1 2069/4885MAPT 1822/4885POLB 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.